Loading data for NTHI — first visit, this takes a few seconds.

알림

NeOnc Technologies Inc. (NTHI)

NasdaqGM: NTHI · 실시간 가격 · USD

4.69

+0.08 (1.74%)

종가 기준: Aug 31, 2026, 3:50 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.74% (1D)

데이터 없음

매수호가	3.41
시가총액	127.35M
매출 (ttm)	39.99K
순이익 (ttm)	-47.2M
	n/a
	-2.12
	n/a
	-4.88
P/B (ttm)	-5.63
P/S (ttm)	3184.48
실적 발표일	Nov 12, 2026

매도호가	3.57
거래량	100,679
평균 거래량 (20일)	151,885
시가	4.57
전일 종가	4.61
일중 범위	4.51 - 4.74
52주 범위	3.00 - 12.99
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

NTHI 소개

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatme...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 26, 2025

직원 수 5

상장 거래소 NasdaqGM

티커 NTHI

웹사이트 https://www.neonc.com

전체 기업 정보

재무 실적

2025년 NeOnc의 매출은 39.99K로, 전년 83K 대비 -51.82% 감소했습니다. 순이익은 -62.15M로, 422.3% 증가했습니다.

재무제표

어닝 서프라이즈

NeOnc가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
EPS -0.58 예상치 하회 -0.41, 및 -Infinity% 전년 대비 감소.

다음 실적 발표

NeOnc Technologies Inc.의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · GuruFocus.com

NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ...

All stockholder proposals approved, including director elections and equity incentive plan expansion, with no financial or operational updates provided.

2주 전 · InvestorsHub

NeOnc Technologies shares jump after positive Phase 2a glioma results

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) shares climbed 11.

3주 전 · Stocktwits

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc” or the "Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancer...

1개월 전 · Stocktwits

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancer...

1개월 전 · Stocktwits

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) ("NeOnc" or the "Company"), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today a...

2 페이지 중 1

NeOnc Technologies Inc. (NTHI)